How Independent Peptide
Testing Works

Independent Peptide Testing With Vanguard Laboratory

Introducing BioPlex Peptides’ Accredited US Laboratory Testing Partner

Independent testing is only as credible as the laboratory conducting it. That is why BioPlex Peptides has chosen to work directly with Vanguard Laboratory, an established analytical testing facility based in Olympia, Washington, USA.

Vanguard is accredited to the internationally recognised ISO/IEC 17025:2017 laboratory standard through A2LA under Certificate Number 6377.01. Its current accreditation is listed as valid until 30 September 2027. Accreditation applies to the specific testing activities defined within Vanguard’s published scope and provides external evidence of its technical competence, documented procedures and laboratory quality-management system.

Vanguard specialises in peptide analysis, research chemicals and wider quality-assurance testing. Depending on the service selected, its capabilities include peptide purity, quantity, concentration, identity and net peptide-content analysis, alongside endotoxin, bioburden, sterility and specified heavy-metals testing.

BioPlex submits selected product samples directly to Vanguard for independent analysis. The laboratory performs the requested tests, reviews the analytical data and provides a detailed report or Certificate of Analysis. BioPlex does not determine or alter the reported findings.

This partnership supports our commitment to building a transparent, regularly updated portfolio of independent testing results—not relying on unsupported manufacturer claims or certificates that cannot be independently verified.

How Independent Peptide Testing Works

Understanding Peptide Purity, Quantity, Identity and Laboratory Analysis, Moving Beyond Unsupported Peptide Purity Claims

A product label, professional-looking vial or unsupported purity percentage cannot independently establish the composition or quality of a peptide sample.

The UK research peptide market has grown substantially, bringing increased competition and lower prices. However, pressure to reduce costs can also result in differences in manufacturing quality, peptide quantity, purity and consistency.

Independent laboratory analysis introduces an additional layer of evidence. Instead of relying exclusively on information supplied by a manufacturer, a physical product sample is submitted to a separate analytical laboratory for examination.

Depending on the analysis selected, testing can investigate the purity, quantity, concentration, identity or net peptide content of the submitted sample. Additional testing can assess endotoxin, bioburden, sterility or specified heavy metals.

The resulting Certificate of Analysis should identify the submitted sample, testing date, analytical method and reported findings. Where applicable, it may also include chromatograms, instrument data and other supporting information.

Independent testing does not eliminate every uncertainty, and no single test answers every quality-related question. It does, however, provide measurable information about the particular sample examined by the laboratory.

Learn About the BioPlex and Vanguard Testing Partnership ⟶

How Does Independent Peptide Testing Work?

Step 1: BioPlex Selects a Product Sample

BioPlex selects products from across its research range for independent testing. Different products will be chosen as the programme develops, allowing us to build a growing portfolio of analytical results.

The relevant product information is recorded before submission. Where available, the sample reference, stated peptide quantity and other identifying information will be associated with the resulting report.

Testing relates only to the specific sample submitted. A result for one sample must not automatically be presented as evidence covering every vial, every manufacturing run or every future product.

Step 2: The Appropriate Tests Are Selected

Different analytical tests answer different questions. BioPlex and Vanguard determine which analyses are appropriate for the selected sample and the information being investigated.

Testing may examine:

Chromatographic purity
Peptide quantity or concentration
Molecular identity
Net peptide content
Endotoxin
Bioburden
Sterility
Specified heavy metals

Not every sample will undergo every available test. The corresponding report should always be checked to establish exactly which analyses were completed.

Step 3: The Sample Is Sent to Vanguard Laboratory

The selected sample is packaged with the required submission information and sent directly to Vanguard Laboratory in Olympia, Washington.

Vanguard states that its standard Level 1 peptide analysis requires one vial. Its more extensive testing levels require additional vials because separate analyses may need their own sample preparation and testing procedures.

After delivery, the laboratory records the submission and places the sample into its analytical testing queue.

Step 4: Laboratory Analysis Begins

The laboratory prepares the submitted sample and performs the requested analysis using the appropriate method and equipment.

Vanguard currently offers three principal levels of peptide testing.

Level 1 Silver Testing

Vanguard’s Level 1 service includes:

HPLC purity analysis
Quantity or concentration analysis
A detailed Certificate of Analysis
An advertised laboratory turnaround of approximately five to eight days

Vanguard currently advertises this service from $250 per submitted sample. Prices and services may change, so the laboratory’s website should be checked for current information.

Level 2 Gold Testing

Vanguard’s Level 2 service includes the Level 1 analysis alongside:

Endotoxin testing
USP bioburden testing
PQ analysis covering identity, purity and net peptide content

Vanguard states that this testing level requires three vials per submitted product.

Level 3 Elite Testing

Vanguard’s Level 3 service includes the Level 2 analyses alongside heavy metals screening:

The laboratory states that this testing level requires four vials per submitted product.

Individual analytical services may also be commissioned separately. The testing level displayed on a Vanguard report should therefore be checked alongside the individual methods and results.

Step 5: The Findings Are Reviewed

Generating analytical data is not the final stage of the process. The recorded information must be reviewed before a laboratory report is issued.

Vanguard states that peptide-testing results undergo quality-control checks and are reviewed by qualified chemists. The completed findings are then provided in a digital report or Certificate of Analysis.

The report records what the laboratory found under the stated analytical conditions. BioPlex does not select, rewrite or amend the reported result.

Step 6: BioPlex Publishes the Certificate

Following receipt, BioPlex will publish eligible certificates within our dedicated testing-results portfolio.

Where supplied, each published result will show:

The product tested
The testing date
The available sample or report reference
The analytical method used

The laboratory’s reported result

Supporting chromatographic or analytical information
The original Vanguard Certificate of Analysis

Publishing the original documentation allows customers and researchers to inspect the available evidence rather than relying solely on a BioPlex summary.

What Can Be Analysed During Peptide Testing?

HPLC Peptide Purity Analysis

High-performance liquid chromatography, normally abbreviated to HPLC, is a laboratory technique used to separate detectable components within a prepared sample.

The sample passes through a chromatography column under controlled conditions. Different components interact with the column and mobile phase in different ways, causing them to leave the column at different times.

A detector records these components as peaks on a chromatogram. The area of the principal peak can then be compared with the combined area of the other detected peaks to calculate relative chromatographic purity under the method used.

A chromatogram provides more information than a purity percentage presented on its own. It allows the main peak, secondary peaks, retention times and baseline to be examined.

However, chromatographic purity is not the same as total peptide quantity, molecular identity, sterility or the absence of every possible contaminant.

Peptide Quantity or Concentration

Quantity testing investigates how much peptide material is measured in the submitted sample.

A sample can produce a high chromatographic-purity result while still containing less peptide material than the total powder weight might suggest. This is because lyophilised material can include water, salts, counterions and other non-peptide components.

For this reason, a result described as 99% purity does not necessarily mean that 99% of the vial’s complete powder weight consists of peptide.

Purity and quantity should be treated as separate measurements:

Purity concerns the relative proportion of the principal detected peptide-related component.
Quantity concerns how much peptide is measured in the submitted sample.

Peptide Identity Analysis

Identity analysis investigates whether the material detected in the sample is consistent with the peptide it is claimed to contain.

A sample could contain a dominant compound and therefore produce a high chromatographic-purity figure. However, purity alone does not necessarily establish that the dominant compound has the expected molecular identity.

Vanguard advertises PQ testing covering identity, purity and net peptide content as part of its more extensive peptide-analysis services. The exact method used and the laboratory’s conclusions should be checked on the individual report.

Identity and purity answer two separate questions:

Is the analysed material consistent with the expected peptide?
How pure is that material under the test method used?

Net Peptide Content

Net peptide content concerns the amount of actual peptide material within a sample after accounting for components that may contribute to its overall mass.

These additional components can include absorbed water, salts and counterions associated with the peptide material. Consequently, total powder weight, chromatographic purity and net peptide content may all produce different figures.

Net peptide-content analysis provides information that cannot be obtained from a headline purity percentage alone.

Endotoxin Testing

Endotoxins are associated with the outer membranes of certain Gram-negative bacteria. They can remain within material even when viable bacteria are no longer detectable.

Vanguard states that its endotoxin testing follows USP <85> methodology. This analysis is separate from peptide-purity testing because HPLC does not determine endotoxin levels.

A high HPLC-purity result should therefore never be presented as evidence that a sample has passed endotoxin analysis unless that separate test was performed.

Bioburden Testing

Bioburden analysis assesses the viable microbial load recovered from a submitted sample under the applied procedure.

Vanguard advertises bioburden analysis following USP <61>. This testing is included within its higher peptide-testing levels and is also advertised as an individual service.

Bioburden testing and sterility testing are not the same. A bioburden result should not automatically be described as proof that a sample is sterile.

Sterility Testing

Vanguard also offers USP <71> sterility testing as an additional analytical service.

Sterility analysis requires a longer testing period because the laboratory must allow sufficient time to detect potential microbial growth. Vanguard advertises a minimum turnaround of approximately 14 days, with its general guidance referring to around 15 days.

A peptide should not be described as sterile because it looks clean, produces a high chromatographic-purity result or has passed a different microbiological test. Sterility claims require the appropriate sterility analysis.

Heavy-Metals Screening

Vanguard’s heavy-metals screening uses inductively coupled plasma mass spectrometry, commonly abbreviated to ICP-MS.

Its advertised peptide screening covers:

Arsenic
Cadmium
Chromium
Mercury
Lead

This analysis investigates the elements specified within the test. It does not prove the absence of every possible contaminant.

The laboratory’s published A2LA scope includes trace-element analysis by ICP-MS, including the five elements covered by Vanguard’s advertised peptide heavy-metals screening.

Bacteriostatic Water Testing

Vanguard also advertises dedicated testing for bacteriostatic water.

Its BAC water analysis covers:

Benzyl-alcohol content
pH
Bioburden

Testing performed on a peptide vial does not automatically provide information about a separate reconstitution solution. Bacteriostatic water must therefore undergo its own appropriate analysis.

Understanding the Different Peptide Test Results

TestWhat it investigatesHPLC purityThe relative proportion of the principal detected component compared with other detected peaksQuantity or concentrationHow much peptide is measured in the submitted sampleIdentityWhether the analysed material is consistent with the expected peptideNet peptide contentThe measured peptide material after accounting for non-peptide componentsEndotoxinDetectable bacterial endotoxin under the specified methodBioburdenRecoverable viable microbial load under the test procedureSterilityWhether the sample meets the requirements of the stated sterility testHeavy metalsWhether specified metallic elements are detected and at what reported levels

No single test provides all of this information. The value of a certificate depends on understanding which analysis was conducted and what that method can—and cannot—establish.

How Long Does Peptide Testing Take?

Vanguard currently advertises a normal turnaround of approximately five to eight days for standard peptide-purity and quantity analysis after laboratory intake.

Endotoxin, heavy-metals and microbiological testing may operate on different timescales. USP sterility testing requires approximately 14 to 15 days because of the incubation period involved.

The complete period between BioPlex selecting a product and publishing its certificate may also include:

Preparing the submission documentation
International delivery to the United States Via DHL Express 24hr
Laboratory intake and queue time
Sample preparation
Additional analytical investigation
Technical review
Final reporting

BioPlex will publish certificates after the completed documentation has been received and checked.

How to Read a Peptide Certificate of Analysis

Check Which Sample Was Tested

The report should identify the submitted product or sample. Where available, check the report number, sample reference and testing date.

Check the Analytical Method

Do not assume every certificate contains the same tests. Establish whether the report covers purity, quantity, identity, endotoxin, bioburden, sterility, heavy metals or a combination of analyses.

Examine the Supporting Data

Where supplied, review the chromatogram, peak information, instrument data and laboratory observations—not only the headline percentage.

Read the Result in Context

A high purity result does not automatically establish identity, quantity, sterility or the absence of contaminants. Each finding should be interpreted according to the method used.

Check the Laboratory

A credible report should identify the laboratory that performed the analysis. Vanguard’s business identity, address and accreditation can be checked independently through the official A2LA directory.

What Does a Certificate of Analysis Actually Prove?

A Certificate of Analysis documents the laboratory’s findings for the specific submitted sample and the specific tests listed on the report.

It does not automatically prove:

The composition of every vial bearing the same product name
The consistency of a different sample
The quality of unrelated products
The absence of substances that were not tested for
Future product consistency
Suitability for human consumption
Sterility when no sterility test was performed

BioPlex will not use one result to imply that every product has undergone the same analysis. We will identify the product tested and present the laboratory’s findings without extending them beyond the available evidence.

Independently Verified Laboratory Accreditation

ISO/IEC 17025:2017 Accreditation Through A2LA

Vanguard Laboratory operates under the legal business name Olympic Analytical, LLC, trading as Vanguard Laboratory.

The laboratory holds ISO/IEC 17025:2017 accreditation through the American Association for Laboratory Accreditation under Certificate Number 6377.01. Its current accreditation is listed as valid until 30 September 2027.

ISO/IEC 17025 is an internationally recognised standard for testing and calibration laboratories. Accreditation involves external evaluation of a laboratory’s technical competence, procedures, equipment, personnel and quality-management system within a defined scope.

Laboratory accreditation does not automatically cover every service offered by an organisation. It applies to the particular activities included within the published accreditation scope.

BioPlex will therefore describe Vanguard as an ISO/IEC 17025:2017-accredited analytical laboratory but will not claim that a specific test is accredited unless it falls within the laboratory’s published scope.

Vanguard’s Verified Accreditation Details

Accreditation informationVerified detailsLegal organisationOlympic Analytical, LLCTrading nameVanguard LaboratoryAccreditation standardISO/IEC 17025:2017Accrediting organisationAmerican Association for Laboratory AccreditationA2LA certificate number6377.01Accredited fieldBiological TestingCurrent expiry date30 September 2027Laboratory locationOlympia, Washington, USA

Verify Vanguard in the Official A2LA Directory ⟶

View Vanguard’s ISO/IEC Certificate and Scope ⟶

BioPlex’s Commitment to Honest Testing Transparency

BioPlex is investing approximately £30,000 over the next 12 months in independent product testing through Vanguard Laboratory.

Our objective is to build a continuing testing programme—not to obtain a small number of certificates and leave them unchanged indefinitely. Different products will be selected over time, and the resulting documentation will be added to our growing testing portfolio.

We will clearly explain:

Which product sample was tested
What analyses were performed
When the testing took place
What the laboratory reported
What the results do and do not establish

Trust should be based on evidence that customers can examine and verify. For this reason, we will publish the available laboratory documentation and provide direct access to Vanguard’s independently verifiable accreditation record.